A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren A. Byers, Martin Förster, Mustafa Özgüroğlu et al.|Clinical Lung Cancer|2021Cited by 39
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C. Bendell, Michael Thomas, Helge Bischoff et al.|Investigational New Drugs|2019Cited by 30